Exagen Historical Balance Sheet

XGN Stock

USD 1.96 0.02 1.01%

Trend analysis of Exagen Inc balance sheet accounts such as Total Assets of 54.2 M, Short Long Term Debt Total of 23.8 M, Other Current Liabilities of 4 M or Total Current Liabilities of 9.7 M provides information on Exagen's total assets, liabilities, and equity, which is the actual value of Exagen Inc to its prevalent stockholders. By breaking down trends over time using Exagen balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Exagen Inc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Exagen Inc is a good buy for the upcoming year.

Exagen Inventory

3.01 Million

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

About Exagen Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Exagen Inc at a specified time, usually calculated after every quarter, six months, or one year. Exagen Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Exagen and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Exagen currently owns. An asset can also be divided into two categories, current and non-current.

Exagen Balance Sheet Chart

At this time, Exagen's Common Stock Shares Outstanding is very stable compared to the past year. As of the 15th of June 2024, Other Current Assets is likely to grow to about 2.1 M, while Total Assets are likely to drop about 54.2 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Exagen assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Exagen Inc books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Exagen balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Exagen Inc are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Exagen's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Exagen Inc current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	27.5M	34.5M	23.7M	23.8M
Total Assets	123.4M	86.2M	56.9M	54.2M

Short Long Term Debt Total Total Assets

Exagen balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock
Total Assets		0.7	0.81	-0.1	0.95	0.54	0.31	-0.94	-0.71	0.65	1.0	0.33	-0.39	1.0	-0.33	0.54	0.86	0.81	0.94	0.91	0.67	0.45	1.0	-0.35	0.83	0.7
Short Long Term Debt Total	0.7		0.83	0.38	0.44	0.58	0.7	-0.41	-0.79	0.88	0.67	0.5	0.14	0.67	-0.42	0.23	0.65	0.78	0.78	0.64	0.99	0.49	0.69	0.06	0.54	0.73
Other Current Liab	0.81	0.83		0.02	0.66	0.63	0.49	-0.62	-0.91	0.87	0.78	0.23	-0.28	0.78	-0.52	0.34	0.82	0.86	0.82	0.85	0.8	0.61	0.81	-0.32	0.74	0.89
Total Current Liabilities	-0.1	0.38	0.02		-0.32	0.04	0.56	0.32	0.0	0.37	-0.14	0.59	0.92	-0.14	-0.01	0.26	-0.07	-0.27	-0.08	-0.08	0.47	0.04	-0.13	0.93	-0.11	0.13
Total Stockholder Equity	0.95	0.44	0.66	-0.32		0.43	0.06	-1.0	-0.55	0.43	0.96	0.17	-0.57	0.96	-0.23	0.56	0.79	0.69	0.85	0.86	0.39	0.34	0.95	-0.5	0.8	0.55
Property Plant And Equipment Net	0.54	0.58	0.63	0.04	0.43		0.26	-0.37	-0.84	0.66	0.5	0.67	-0.06	0.5	-0.94	0.5	0.8	0.56	0.57	0.73	0.56	0.95	0.51	-0.19	0.71	0.82
Current Deferred Revenue	0.31	0.7	0.49	0.56	0.06	0.26		-0.07	-0.46	0.64	0.28	0.38	0.38	0.28	-0.2	0.07	0.28	0.38	0.34	0.26	0.75	0.25	0.29	0.36	0.2	0.44
Net Debt	-0.94	-0.41	-0.62	0.32	-1.0	-0.37	-0.07		0.51	-0.39	-0.95	-0.15	0.56	-0.95	0.18	-0.55	-0.76	-0.65	-0.82	-0.82	-0.37	-0.29	-0.94	0.47	-0.78	-0.51
Retained Earnings	-0.71	-0.79	-0.91	0.0	-0.55	-0.84	-0.46	0.51		-0.84	-0.67	-0.38	0.21	-0.67	0.79	-0.34	-0.89	-0.81	-0.74	-0.81	-0.76	-0.86	-0.7	0.32	-0.8	-0.92
Accounts Payable	0.65	0.88	0.87	0.37	0.43	0.66	0.64	-0.39	-0.84		0.61	0.53	0.08	0.61	-0.55	0.41	0.72	0.68	0.74	0.74	0.88	0.62	0.63	0.05	0.63	0.85
Cash	1.0	0.67	0.78	-0.14	0.96	0.5	0.28	-0.95	-0.67	0.61		0.28	-0.42	1.0	-0.28	0.52	0.83	0.79	0.93	0.89	0.62	0.4	1.0	-0.37	0.81	0.66
Non Current Assets Total	0.33	0.5	0.23	0.59	0.17	0.67	0.38	-0.15	-0.38	0.53	0.28		0.5	0.28	-0.51	0.56	0.4	0.13	0.32	0.4	0.55	0.54	0.28	0.46	0.33	0.5
Non Currrent Assets Other	-0.39	0.14	-0.28	0.92	-0.57	-0.06	0.38	0.56	0.21	0.08	-0.42	0.5		-0.42	0.02	0.08	-0.31	-0.48	-0.35	-0.34	0.23	-0.06	-0.42	0.95	-0.34	-0.09
Cash And Short Term Investments	1.0	0.67	0.78	-0.14	0.96	0.5	0.28	-0.95	-0.67	0.61	1.0	0.28	-0.42		-0.28	0.52	0.83	0.79	0.93	0.89	0.62	0.4	1.0	-0.37	0.81	0.66
Good Will	-0.33	-0.42	-0.52	-0.01	-0.23	-0.94	-0.2	0.18	0.79	-0.55	-0.28	-0.51	0.02	-0.28		-0.44	-0.73	-0.4	-0.38	-0.6	-0.41	-0.98	-0.31	0.18	-0.67	-0.76
Common Stock Total Equity	0.54	0.23	0.34	0.26	0.56	0.5	0.07	-0.55	-0.34	0.41	0.52	0.56	0.08	0.52	-0.44		0.65	0.08	0.47	0.71	0.26	0.48	0.52	0.18	0.71	0.54
Common Stock Shares Outstanding	0.86	0.65	0.82	-0.07	0.79	0.8	0.28	-0.76	-0.89	0.72	0.83	0.4	-0.31	0.83	-0.73	0.65		0.71	0.84	0.94	0.62	0.81	0.85	-0.34	0.98	0.85
Non Current Liabilities Total	0.81	0.78	0.86	-0.27	0.69	0.56	0.38	-0.65	-0.81	0.68	0.79	0.13	-0.48	0.79	-0.4	0.08	0.71		0.86	0.73	0.72	0.47	0.81	-0.57	0.62	0.69
Other Current Assets	0.94	0.78	0.82	-0.08	0.85	0.57	0.34	-0.82	-0.74	0.74	0.93	0.32	-0.35	0.93	-0.38	0.47	0.84	0.86		0.88	0.73	0.45	0.94	-0.34	0.81	0.67
Other Stockholder Equity	0.91	0.64	0.85	-0.08	0.86	0.73	0.26	-0.82	-0.81	0.74	0.89	0.4	-0.34	0.89	-0.6	0.71	0.94	0.73	0.88		0.61	0.68	0.9	-0.34	0.92	0.87
Total Liab	0.67	0.99	0.8	0.47	0.39	0.56	0.75	-0.37	-0.76	0.88	0.62	0.55	0.23	0.62	-0.41	0.26	0.62	0.72	0.73	0.61		0.49	0.65	0.15	0.52	0.72
Property Plant And Equipment Gross	0.45	0.49	0.61	0.04	0.34	0.95	0.25	-0.29	-0.86	0.62	0.4	0.54	-0.06	0.4	-0.98	0.48	0.81	0.47	0.45	0.68	0.49		0.42	-0.19	0.74	0.82
Total Current Assets	1.0	0.69	0.81	-0.13	0.95	0.51	0.29	-0.94	-0.7	0.63	1.0	0.28	-0.42	1.0	-0.31	0.52	0.85	0.81	0.94	0.9	0.65	0.42		-0.38	0.83	0.68
Short Term Debt	-0.35	0.06	-0.32	0.93	-0.5	-0.19	0.36	0.47	0.32	0.05	-0.37	0.46	0.95	-0.37	0.18	0.18	-0.34	-0.57	-0.34	-0.34	0.15	-0.19	-0.38		-0.34	-0.17
Intangible Assets	0.83	0.54	0.74	-0.11	0.8	0.71	0.2	-0.78	-0.8	0.63	0.81	0.33	-0.34	0.81	-0.67	0.71	0.98	0.62	0.81	0.92	0.52	0.74	0.83	-0.34		0.76
Common Stock	0.7	0.73	0.89	0.13	0.55	0.82	0.44	-0.51	-0.92	0.85	0.66	0.5	-0.09	0.66	-0.76	0.54	0.85	0.69	0.67	0.87	0.72	0.82	0.68	-0.17	0.76

Click cells to compare fundamentals

Exagen Account Relationship Matchups

Exagen balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	88.3M	78.4M	123.4M	86.2M	56.9M	54.2M
Short Long Term Debt Total	25.9M	26.7M	27.5M	34.5M	23.7M	23.8M
Other Current Liab	4.2M	5.4M	6.2M	5.3M	7.0M	4.0M
Total Current Liabilities	5.9M	8.8M	9.3M	9.6M	11.9M	9.7M
Total Stockholder Equity	55.7M	41.8M	84.9M	42.5M	22.7M	20.5M
Property Plant And Equipment Net	1.4M	2.1M	4.8M	13.1M	8.5M	8.9M
Net Debt	(46.2M)	(30.8M)	(72.0M)	(27.9M)	(12.8M)	(13.4M)
Retained Earnings	(164.6M)	(181.3M)	(208.1M)	(255.5M)	(279.2M)	(265.3M)
Accounts Payable	1.5M	3.0M	2.5M	3.0M	3.1M	2.1M
Cash	72.1M	57.4M	99.4M	62.4M	36.5M	37.0M
Non Current Assets Total	7.1M	7.9M	10.7M	13.6M	9.1M	10.2M
Non Currrent Assets Other	503K	174K	(487K)	(391K)	528K	416K
Cash And Short Term Investments	72.1M	57.4M	99.4M	62.4M	36.5M	37.0M
Common Stock Shares Outstanding	12.6M	12.7M	16.0M	17.1M	17.7M	18.6M
Liabilities And Stockholders Equity	88.3M	78.4M	123.4M	86.2M	56.9M	54.2M
Non Current Liabilities Total	26.8M	27.8M	29.2M	34.1M	22.3M	20.3M
Other Current Assets	3.5M	4.2M	3.6M	4.1M	1.9M	2.1M
Other Stockholder Equity	220.2M	223.1M	293.1M	298.0M	301.9M	164.6M
Total Liab	32.7M	36.5M	38.5M	43.8M	34.3M	33.7M
Property Plant And Equipment Gross	1.4M	2.1M	4.8M	13.1M	14.3M	15.0M
Total Current Assets	81.3M	70.5M	112.7M	72.6M	47.8M	44.0M
Short Term Debt	238K	308K	587K	1.2M	1.7M	1.6M
Other Assets	174K	250K	433K	528K	475.2K	894.3K
Net Receivables	5.7M	8.9M	9.7M	6.1M	6.6M	6.0M
Property Plant Equipment	1.4M	2.1M	4.8M	13.1M	15.0M	15.8M
Other Liab	266K	530K	1.7M	19K	17.1K	16.2K
Net Tangible Assets	50.2M	36.3M	79.4M	42.5M	48.8M	51.3M
Long Term Debt	25.9M	26.7M	27.5M	28.8M	19.2M	21.0M
Capital Lease Obligations	238K	308K	587K	6.2M	4.2M	4.4M
Inventory	1.4M	1.2M	1.1M	1.8M	2.9M	3.0M
Non Current Liabilities Other	638K	948K	1.4M	867K	357K	567.1K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Additional Information and Resources on Investing in Exagen Stock

When determining whether Exagen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Exagen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Exagen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Exagen Inc Stock:

How To Invest In Exagen

Details

Is Exagen Stock a good investment?

Details

What is Exagen's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.09)

Revenue Per Share

3.134

Quarterly Revenue Growth

0.284

Return On Assets

(0.17)

Return On Equity

(0.69)

The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Exagen Historical Balance Sheet

Exagen Inventory

3.01 Million

About Exagen Balance Sheet Analysis

Exagen Balance Sheet Chart

Total Assets

Total Current Liabilities

Exagen balance sheet Correlations

Exagen Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Exagen balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Additional Information and Resources on Investing in Exagen Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments

Net Debt	- 1.0	Total Stockholder Equity
Property Plant And Equipment Gross	- 0.98	Good Will
Cash And Short Term Investments	- 0.95	Net Debt
Cash	- 0.95	Net Debt
Total Current Assets	- 0.94	Net Debt
Good Will	- 0.94	Property Plant And Equipment Net